SysMedPD: Systems Medicine of Mitochondrial Parkinson’s Disease
SysMedPD is a Horizon2020 project with the aim to discover and develop novel drug candidates to slow down Parkinson’s disease with overt mitochondrial dysfunction.
Personalized Medicine is one of the most innovative areas in the future of health research with a high potential for patients, citizens and the economy. To deploy the full potential of Personalized Medicine, the CSA PerMed was initiated to step up coordination efforts between European key stakeholders to allow synergies and avoid duplication or competition, to ensure maximum transparency and openness preparing Europe for leading the global way.
The treatment of complex disease like allergy, obesity and cancer is complicated by variable response to medication. This causes both increased suffering and costs. Ideally, physicians should be able to routinely personalize medication based on a few diagnostic markers. Finding such markers is a formidable challenge.
The aim of SYSCILIA is to identify the molecular mechanisms characterizing cilium function, and the discrete perturbations associated with dysfunction caused by mutations in inherited ciliopathies, applying a systems biology approach.